Skip to main content
Premium Trial:

Request an Annual Quote

Markus Bhm, Alistair Rees, Gregory May, Jim Huntley, Steven Day, Affymetrix, ParAllele BioScience


People in the News

Markus Böhm has left his position as international product manager of microarray solutions at Schott-Nexterion, Böhm informed BioArray News this week.

He will begin working for Illumina in January 2006 and will be responsible for the San Diego-based array company's accounts in Germany, Austria, and Switzerland.

Böhm said that Alistair Rees has taken his position at Schott.

The National Center for Genome Resources announced three senior appointments last week: Gregory May as leader of the Nutritional Biology Program, Jim Huntley as senior research scientist, and Steven Day as director of software engineering.

Previously, May was associate scientist and head of the Medicago Genomics Program at the Samuel Roberts Noble Foundation in Ardmore, Okla., for six years and assistant scientist at the Boyce Thompson Institute for Plant Research at Cornell University for four years. He holds a PhD in plant physiology and biotechnology from Texas A&M University and a BS in biology from Southeast Missouri State University.

Huntley was assistant professor at New Mexico Highlands University and director of the NMHU Research Infrastructure in Minority Institutions program prior to NCGR. Huntley holds a PhD in biochemistry from Arizona State University, an MS in medical physics and a BA in physics from the University of Colorado, Boulder.

Before joining NCGR, Day was director of information technology at the Molecular Profiling Institute, Phoenix. Prior to this, he led the software engineering unit within the Translational Genomics Research Institute and worked for SRA International. Day holds a BA in chemistry and an MS in computer science from Johns Hopkins University.


New Product Watch

Affymetrix this week launched standard and custom SNP panels for targeted genotyping applications.

The available panels, which span 1,500 to 20,000 SNPs per assay, include 20K cSNP, 10K cSNP, and 3K Mapping by Admixture Linkage Disequilibrium for whole-genome association analysis studies, a 9K Immune-Inflammation Panel for disease-related candidate gene studies, and 10K Bovine, 5K Mouse, and 5K Rat panels for common animal research.

The new SNP panels use molecular inversion probe assay technology first demonstrated through ParAllele BioScience's MegAllele assay, and are the first MIP products to be released since Affy acquired ParAllele in October (see BAN 10/26/2005).

Affymetrix said it plans to introduce new standard SNP panels for applications that include cancer, cardiovascular disease and other important medical conditions over the next few months.

Separately, Affy also released its GeneChip Human Mitochondrial Resequencing Array 2.0, which it claims enables researchers to analyze the entire sequence of the mitochondrial genome in a single 48 hour experiment.

Affy said the Mitochondrial Array interrogates 16,500 bases of the human mitochondrial genome with only three PCR reactions, adding that the method could be used for detecting variants associated with genetic disease, forensics, population studies or stem cells.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.